Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:13 pm Sale |
2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Venrock Healthcare Capital Partners III L.P. | 2,457,348 4.400% |
-1,001,297 (-28.95%) |
Filing History |
| 2025-02-14 3:45 pm Purchase |
2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Fairmount Funds Management LLC | 5,869,037 9.900% |
992 (+0.02%) |
Filing History |
| 2025-02-12 08:46 am Sale |
2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
FMR CORP | 7,823,729 13.900% |
-639,949 (-7.56%) |
Filing History |
| 2025-01-28 4:00 pm Sale |
2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Integrated Core Strategies (US) LLC | 1,994,503 3.500% |
-954,373 (-32.36%) |
Filing History |
| 2025-01-07 07:45 am Purchase |
2024-12-30 | 13G | Astria Therapeutics, Inc. ATXS |
ForGrowth III PA B.V. | 2,872,537 5.100% |
2,872,537 (New Position) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
RA Capital Management, L.P. | 5,105,213 9.000% |
692,063 (+15.68%) |
Filing History |
| 2024-11-14 5:45 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
Venrock Healthcare Capital Partners III L.P. | 3,458,645 6.100% |
232,839 (+7.22%) |
Filing History |
| 2024-11-14 4:41 pm Unchanged |
2024-11-14 | 13D | Astria Therapeutics, Inc. ATXS |
PERCEPTIVE ADVISORS LLC | 6,485,420 11.500% |
0 (Unchanged) |
Filing History |
| 2024-11-14 4:15 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
Fairmount Funds Management LLC | 5,868,045 9.900% |
2,234,080 (+61.48%) |
Filing History |
| 2024-11-14 12:03 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
Vestal Point Capital, LP | 4,000,000 7.100% |
4,000,000 (New Position) |
Filing History |
| 2024-11-13 4:21 pm Sale |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
TCG Crossover GP II, LLC | 2,761,861 4.900% |
-1,607,067 (-36.78%) |
Filing History |
| 2024-11-12 1:29 pm Unchanged |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
The Vanguard Group | 2,635,520 4.670% |
0 (Unchanged) |
Filing History |
| 2024-11-12 09:50 am Purchase |
2024-11-08 | 13G | Astria Therapeutics, Inc. ATXS |
FMR CORP | 8,463,678 14.999% |
1,767,714 (+26.40%) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
BLACKROCK INC BLK |
3,499,478 6.200% |
0 (Unchanged) |
Filing History |
| 2024-11-04 12:37 pm Unchanged |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
The Vanguard Group | 2,635,520 4.670% |
0 (Unchanged) |
Filing History |
| 2024-11-04 11:39 am Unchanged |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
The Vanguard Group | 2,635,520 4.670% |
0 (Unchanged) |
Filing History |
| 2024-11-04 11:39 am Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
The Vanguard Group | 2,635,520 4.670% |
579,813 (+28.21%) |
Filing History |
| 2024-11-01 4:05 pm Purchase |
2024-10-28 | 13G | Astria Therapeutics, Inc. ATXS |
Integrated Core Strategies (US) LLC | 2,948,876 5.200% |
2,948,876 (New Position) |
Filing History |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS |
BLACKROCK INC BLK |
3,499,478 6.200% |
1,043,825 (+42.51%) |
Filing History |
| 2024-07-10 10:10 am Purchase |
2024-07-09 | 13G | Astria Therapeutics, Inc. ATXS |
FMR CORP | 6,695,964 12.193% |
1,732,228 (+34.90%) |
Filing History |